MEDICENNA THERAPEUTICS CORP (MDNA) Forecast, Price Target & Analyst Ratings

NASDAQ:MDNA • CA58490H1073

0.157 USD

-0.02 (-13.16%)

At close: Nov 1, 2023

0.1565 USD

0 (-0.32%)

After Hours: 11/1/2023, 8:00:01 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MEDICENNA THERAPEUTICS CORP (MDNA).

Consensus Price Target

Price Target

$2.88

+ 1,735.48% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: Nov 9, 2023
Period: Q2 / 2024
EPS Estimate: -CA$0.07
Revenue Estimate

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

83.64%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$2.88

Upside

+ 1,735.48%

From current price of $0.16 to mean target of $2.88, Based on 11 analyst forecasts

Low

$1.14

Median

$2.41

High

$5.97

Price Target Revisions

1 Month

-26.64%

3 Months

-18.64%

Price Target Summary

11 Wall Street analysts provided a forecast for the next 12 months for MDNA. The average price target is 2.88 USD. This implies a price increase of 1735.48% is expected in the next year compared to the current price of 0.157.

The average price target has been revised downward by 18.64% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

83.64%

MDNA was analyzed by 11 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about MDNA.

In the previous month the buy percentage consensus was at a similar level.

MDNA was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2024-12-06	HC Wainwright & Co.	Reiterate	Buy -> Buy
2023-08-14	Oppenheimer	Maintains	Outperform -> Outperform
2023-08-10	HC Wainwright & Co.	Reiterate	Buy -> Buy
2023-07-31	HC Wainwright & Co.	Reiterate	Buy -> Buy
2023-06-28	HC Wainwright & Co.	Reiterate	Buy -> Buy
2023-02-08	HC Wainwright & Co.	Reiterate	Buy
2022-11-08	HC Wainwright & Co.	Maintains	Buy
2022-08-16	HC Wainwright & Co.	Maintains	Buy
2022-06-23	Oppenheimer	Maintains	Outperform
2022-06-23	HC Wainwright & Co.	Maintains	Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date: Nov 9, 2023
Period: Q2 / 2024
EPS Estimate: -CA$0.07
Revenue Estimate
Revenue Q2Q: N/A
EPS Q2Q: -68.30%
Number of Analysts: 7

Next Earnings Revisions

Revenue (1 Month)

N/A

Revenue (3 Months)

N/A

EPS (1 Month)

1.00%

EPS (3 Months)

5.71%

Next Earnings Summary

MDNA is expected to report earnings on 11/9/2023. The consensus EPS estimate for the next earnings is -0.07 USD and the consensus revenue estimate is 0 USD.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
Revenue YoY % growth									N/A	N/A	N/A 21.74%	N/A 5,088.05%	N/A 20.67%	N/A 48.63%	N/A 46.37%
EBITDA YoY % growth	N/A	-80K	-7.42M -9,175.00%	-4.72M 36.39%	-8.23M -74.36%	-17.36M -110.94%	-22.435M -29.23%	-16.299M 27.35%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT YoY % growth	-200K	-90K 55.00%	-7.43M -8,155.56%	-4.73M 36.34%	-8.24M -74.21%	-17.4M -111.17%	-22.473M -29.16%	-16.303M 27.46%	N/A -25.39%	N/A -23.07%	N/A -15.89%	N/A 75.31%	N/A 285.98%	N/A 122.21%	N/A 83.37%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS YoY % growth	N/A	N/A	N/A	-0.22 40.09%	-0.26 -18.18%	-0.35 -34.62%	-0.42 -20.00%	-0.19 54.76%	N/A -26.16%	N/A -21.99%	N/A -5.35%	N/A 299.80%	N/A	N/A	N/A

All data in CAD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q2 / 24	Q3 / 24	Q4 / 24	Q1 / 25	Q2 / 25	Q3 / 25	Q4 / 25
EPS Q2Q % growth	-0.07 -68.30%	-0.08 -277.40%	-0.07 -12.20%	-0.08 -104.00%	-0.08 -21.21%	-0.08 -8.11%	-0.08 -13.64%
Revenue Q2Q % growth
EBITDA Q2Q % growth	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT Q2Q % growth	-5.314M -12.27%	-5.929M -20.48%	-5.439M -134.54%	-6.229M -39.69%	-6.307M -18.69%	-6.639M -11.98%	-7.38M -35.69%

All data in CAD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

-17.48%

EPS Next 5 Year

51.29%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

N/A

Revenue Next 5 Year

N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

N/A

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

MEDICENNA THERAPEUTICS CORP / MDNA Forecast FAQ

Can you provide the average price target for MEDICENNA THERAPEUTICS CORP stock?

11 analysts have analysed MDNA and the average price target is 2.88 USD. This implies a price increase of 1735.48% is expected in the next year compared to the current price of 0.157.

Can you provide the upcoming earnings date for MEDICENNA THERAPEUTICS CORP?

MEDICENNA THERAPEUTICS CORP (MDNA) will report earnings on 2023-11-09, before the market open.

What are the consensus estimates for MDNA stock next earnings?

The consensus EPS estimate for the next earnings of MEDICENNA THERAPEUTICS CORP (MDNA) is -0.07 USD and the consensus revenue estimate is 0 USD.

How many analysts have analysed MEDICENNA THERAPEUTICS CORP (MDNA)?

The number of analysts covering MEDICENNA THERAPEUTICS CORP (MDNA) is 11.

Analyst forecast overview

Forecast Snapshot